Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2026 07:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of...
February 23, 2026 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
February 17, 2026 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
February 05, 2026 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
January 07, 2026 16:01 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
November 19, 2025 10:22 ET | Source: Research and Markets

Necrotizing Enterocolitis Market Research and Forecast Report 2025-2035: Increasing R&D Investments in Microbiome Modulation, Immunotherapy, and Novel Biologics are Opening New Avenues

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Necrotizing Enterocolitis Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnosis, End User, Country, and Region - Analysis and...
October 30, 2025 07:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses...
October 20, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
October 06, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens...
September 22, 2025 10:36 ET | Source: Research and Markets

Gastroenterology - Global Strategic Business Report 2025 Featuring Analysis of 41 Industry Players

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was...